Neutralizing antibodies of BMP-6 have been widely used to block hepcidin production in preclinical and clinical models of anemia in chronic diseases, such as chronic kidney disease, which also exhibit a potential role in reducing the need for EPO [136, 137]. Here, EPO is linked to anemia (phenotype).